Global Strategic Business Report on Pulmonary Arterial Hypertension (PAH) Therapeutics 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ Million.

The global market is analyzed by the following Drug Class and Brands:

  • Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer)
  • Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram)
  • PDE-5 Inhibitors (Cialis/Adcirca, & Revatio)
  • Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)

The report profiles 31 companies including many key and niche players such as:

  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (US)
  • Pfizer, Inc. (US)
  • United Therapeutics Corporation (US)
  • Lung Biotechnology PBC (US)

Key Topics Covered

1. INDUSTRY OVERVIEW

  • Pulmonary Arterial Hypertension (PAH) - A Prelude
  • Current & Future Analysis
  • PAH Drugs Market by Class
  • The PAH Classification
  • PH Patient Groupings as per World Health Organization
  • Classification of PAH patients as per New York Heart Association (NYHA)
  • Oral Therapies lead the Global PAH Therapeutics Market
  • Combination Therapy Favored over Monotherapy for PAH
  • Pediatric PAH - A Potential Market with Unmet Need
  • Inflammation: New Target for PAH Therapeutics
  • Aging Population & PAH

2. COMPETITIVE SCENARIO

3. PAH PIPELINE

4. PRODUCT OVERVIEW

5. PRODUCT INNOVATIONS & APPROVALS

6. RECENT INDUSTRY ACTIVITY

7. FOCUS ON SELECT GLOBAL PLAYERS

8. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 31 (including Divisions/Subsidiaries 33)

  • The United States (18)
  • Japan (3)
  • Europe (10)
    • France (1)
    • Germany (3)
    • The United Kingdom (3)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (1)
  • Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/l7bj7r/global_strategic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs